Hypothesis

Chronic activation of corticotropin‑releasing factor (CRF)–expressing neurons in the paraventricular nucleus drives a neuroendocrine cascade that accelerates multiple hallmarks of aging through dysregulation of the AMPK‑SIRT1 mitochondrial axis. Conversely, enhancing AMPK‑SIRT1 signaling specifically in CRF neurons suppresses HPA‑axis output, improves peripheral mitochondrial fidelity, and delays aging phenotypes.

Mechanistic Rationale

1. CRF neurons as metabolic sensors – CRF‑expressing cells exhibit high basal AMPK activity and express SIRT1, linking cellular energy status to neuropeptide release. Nutrient scarcity activates AMPK, which deacetylates and activates SIRT1, leading to reduced CRF transcription via FOXO1‑mediated chromatin remodeling.
2. Neuroendocrine efferents – Lower CRF release diminishes ACTH and glucocorticoid secretion, decreasing systemic catecholamine drive. Reduced glucocorticoid signaling lessens NADPH oxidase activation in peripheral immune cells, curbing ROS production that otherwise fuels mitochondrial DNA damage and epigenetic drift.
3. Mitochondrial‑epigenetic feedback loop – Peripheral ROS normally activates p38 MAPK, which phosphorylates DNMT3A and TET2, promoting maladaptive methylation at promoters of PGC‑1α and SIRT3. By lowering ROS, CRF‑neuron AMPK‑SIRT1 activation preserves PGC‑1α expression and SIRT3‑mediated deacetylation of MnSOD, sustaining mitochondrial ROS scavenging.
4. Cross‑talk with nutrient‑sensing networks – Improved mitochondrial NAD+ levels boost systemic SIRT1 activity, reinforcing AMPK activation in liver, muscle, and adipose tissue. This creates a positive feedback loop where peripheral metabolic health further stabilizes central CRF neuron firing.

Testable Predictions

• Genetic/chemogenetic activation of AMPK (via AAV‑CaMKIIα‑AMPKα1‑CA) or SIRT1 (AAV‑CRF‑SIRT1) in mouse CRF neurons will:
  • Decrease basal plasma corticosterone and catecholamines.
  • Increase hepatic and skeletal‑muscle PGC‑1α acetylation status and SIRT3 activity.
  • Reduce markers of senescence (p16^INK4a^), proteotoxicity (ubiquitinated proteins), and genomic instability (γH2AX foci) in peripheral tissues.
  • Extend median lifespan by ~15% compared with controls.
• Inhibition of AMPK or SIRT1 in CRF neurons (AAV‑CRF‑AMPKα1‑DN or SIRT1‑shRNA) will produce the opposite phenotype, accelerating aging hallmarks despite unchanged caloric intake.
• Rescue experiments: Peripheral administration of a mitochondrially targeted antioxidant (MitoQ) will not replicate the full lifespan extension seen with central AMPK‑SIRT1 activation, indicating that neuroendocrine modulation is necessary.
• Human relevance: PET‑MRI CRF receptor binding in the hypothalamus will inversely correlate with circulating NAD+ metabolites and mitochondrial DNA copy number in leukocytes across age cohorts.

Falsifiability

If cell‑type‑specific modulation of AMPK or SIRT1 in CRF neurons fails to alter peripheral mitochondrial function, inflammatory cytokines, or aging‑related biomarkers, the hypothesis that this neuronal axis serves as a master integrator of systemic aging is refuted. Similarly, if lifespan extension occurs without measurable changes in HPA‑axis output, the proposed causal pathway is invalid.

Implications

This model reframes the hallmarks of aging as downstream manifestations of a hierarchical neuro‑metabolic control system, positioning the CRF‑AMPK‑SIRT1 node as a viable target for interventions that coordinate multiple aging processes simultaneously.